MELEMA Pharma GmbH, a private biopharmaceutical company, is focusing on the development of immunotherapeutics having the potential to activate the patient’s own immune system. A substantial medical challenge for the company is the immuno-oncology. The compounds under development are mainly based on natural compounds optimised by modern Gene Technological Procedures.
Lead product is the immunepotentiator Aviscumine (ME-503), a therapeutic protein which recently completed a Phase II study in patients with refractory metastatic melanoma (stage IV) and for which the further clinical development is in preparation.
MELEMA Pharma’s strategy is to develop its drug candidates to Proof of Concept, and then bring in partners from academia and industry for the final stages of product development and commercialization.